T h e lysosomal system is the main intracellular mechanism for the catabolism of naturally occurring endogenous and exogenous macromolecules and the subsequent recycling of their constituent monomeric components. It also plays an important part in processing essential metabolites.
Introduction
T h e lysosomal system is the main intracellular mechanism in eukaryotic cells for the catabolism of naturally occurring macromolecules, which may arise from within or outside a cell (for a comprehensive review of the biology of lysosomes see [l] ). It also plays an important part in processing several essential metabolites. Material to be catabolized or processed is delivered to the lysosomes either by direct engulfment or by fusion of digestive vacuoles with the lysosomes. Catabolism takes place within the lumen of the lysosomes at an acidic pH, which is maintained by a specific proton pump in the lysosomal membrane. This catabolism is catalysed by a mixture of enzymes, which collectively have the capacity to degrade all naturally occurring macromolecules to their constituent monomeric components, which can then pass through the lysosomal membrane for reutilization by the cell. T h e pathways for the lysosomal catabolism of most macromolecules have been established [l] . T h e enzymes in these pathways are predominantly soluble hydrolases, which have characteristic acidic p H optima and are localized in the lumen of the lysosome. They are all glycoproteins and are synthesized on ribosomes associated with the rough endoplasmic reticulum as inactive precursors and transported to the lysosomes via the endoplasmic reticulum and the Golgi compartment. During their transport from their site of synthesis to their site of action they undergo essential post-translational modification, including proteolysis, glycosylation and phosphorylation [2]. In particular they acquire a specific lysosomal-recognition marker, mannose 6-phosphate, which is recognized by specific mannose 6-phosphate receptors (MPRs) in the Golgi compartment. Binding to the MPRs segregates the proteins destined for the lumen of the lysosome from other glycoproteins. T h e MPR-lysosome enzyme-precursor complex is delivered to a pre-lysosomal compartment, where dissociation occurs. T h e receptor recycles to the trans-Golgi network or the plasma membrane and the lysosomal enzyme precursors are transported to lysosomes where the final steps in their maturation occur. These include proteolysis, folding, aggregation and possibly dephosphorylation. T h e lysosomal sulphatases undergo a novel oxidation of the thiol group of a conserved cysteine to an aldehyde in the endoplasmic reticulum [3]. Some lysosomal enzymes that act on lipophilic substrates require a non-enzymic protein co-factor, a sphingolipid activator protein or saposin, to function [4]. Four saposins are derived from a common precursor, prosaposin, which is also transported to the lysosomes by the mannose 6-phosphaterecognition pathway. A few lysosomal enzymes are associated with the lysosomal membrane. Although they are glycoproteins they are transported to the lysosomes by an alternative route that does not utilize the mannose 6-phosphate marker. An alternative delivery route may also exist for the luminal enzymes in certain cells [2] .
T h e low-molecular-mass products of lysosomal digestion can pass through the lysosomal membrane, whereas the membrane is impermeable to undigested or partially digested material. Egress from the lysosomes is either by passive diffusion or by specific metabolite transporters [S] . Two transporters, for cystine [6] and sialic acid [7] , have recently been cloned. Several other lysosomal membrane proteins have been isolated and cloned but their functions are not known [8] . They are not transported to the lysosomes by the mannose 6-phosphate pathway but are either delivered to the endosomall lysosomal system directly in clathrin-coated vesicles or indirectly via the plasma membrane after following the default secretory pathway for glycoproteins. Signals in the short cytosolic domain of these proteins mediate their sorting and delivery to the lysosomes.
A genetic defect in a lysosomal enzyme, its protein cofactor, a lysosomal membrane protein or in a protein involved in the post-translational modification or transport of lysosomal proteins will disrupt lysosomal function. In consequence, partially digested molecules, or in the case of a transporter defect, the substrate, will accumulate progressively within lysosomes. This is the pathological condition called a lysosomal storage disease. T h e progressive hypertrophy of the lysosomal system leads to a wide range of clinical symptoms that depend on the protein defect, the nature of the stored material and the cells in which the material is stored. T h e pathogenesis of lysosomal storage diseases is poorly understood [9] . Over 40 different lysosomal storage diseases have been described in humans [lo] , with an overall prevalence of approximately 1 in 7000-8000 live births [ l l ] . Diagnosis is based on clinical symptoms followed by demonstration of a deficiency of a specific enzyme activity or transporter. Most of the genes for the proteins involved in the lysosomal system have been cloned, permitting mutation analysis in individual cases. This information is very useful for carrier detection and genetic counselling within families and for investigating the relationship between genotype and phenotype. T h e lysosomal storage diseases are very heterogeneous genetically. A full understanding of the molecular basis of a lysosomal storage disease is becoming increasingly important for the selection of patients for the novel forms of therapy becoming available.
Many naturally occurring lysosomal storage diseases have also been reported in animals [12] and they have been used to investigate the pathogenesis of the disorders and therapeutic strategies. More recently many mouse models of the corresponding human disease have been created by targeted disruption of specific genes [ 13,141.
Approaches to therapy can be considered at two levels, dispersal or restriction of the storage material and replacement of the defective protein (Figure 1) . Dispersal of the storage products is probably only applicable to transport defects in which low-molecular-mass material has accumulated within the lysosomes. The intralysosomal accumulation of cystine in cystinosis can be decreased by high oral doses of the drug cysteamine, which is a weak base that accumulates naturally within lysosomes. There it reacts with the accumulated cystine to form a mixed disulphide, which bears a strong structural resemblance to lysine and is transported out of the lysosomes by the lysine transporter. If used early, in high doses, cysteamine can prevent renal deterioration and lead to improvement in growth but does not alter other aspects of the disease [15] . T h e cloning of the cystine transporter, cystinosin, raises the possibility of correction by gene therapy.
Restricting the flow of substrates to the lysosomes or substrate deprivation has been achieved in cells in culture and in mouse models of glycolipid storage diseases [ 161. N-Butyldeoxynojirimycin, which was originally developed as an anti-HIV drug, is an effective inhibitor in vitvo and in vivo of glucosyltransferase, the first enzyme in the pathway for the assembly of the oligosaccharide chains of glycolipids (Figure 2 ). Therefore it can decrease the rate of synthesis of all the glycolipids based on glucosylceramide and is potentially a generic drug for the glycosphingolipidoses, including those with central-nervoussystem involvement. It is currently in clinical trial in patients with Fabry and Gaucher type-1 diseases. T h e galactose analogue, N-butyldeoxygalactonojirimycin, is a more selective inhibitor and potentially may be a superior drug for therapy.
Replacement of the defective protein can be achieved by direct administration of the purified protein, transplant of cells producing the normal protein or by transfer of the gene encoding the protein (Figure 1 ).
Endocytosis provides a natural mechanism for delivery of exogenous enzyme to the storage material in the lysosomes. As all lysosomal enzymes are glycoproteins, it is possible to exploit endocytosis mediated by the carbohydrate-recognizing receptors to enhance the uptake of circulating enzyme and to target the enzyme to different cells. Enzyme-replacement therapy (ERT) is an established and effective treatment for the nonneuronopathic form of Gaucher disease (type l), which results from a deficiency of B-D-glucocerebrosidase [ 171. The N-linked oligosaccharides on recombinant B-D-glucocerebrosidase are modified enzymically to terminate in mannose, which is recognized by the mannose receptor on macrophages, the major target cell for the replacement enzyme. Exogenous lysosomal enzymes carrying the lysosomal tag, mannose 6-phosphate, can be delivered to a wide range of cells via the ubiquitous MPRs on cell surfaces. Over-production of recombinant human lysosomal enzymes in mammalian cells can be controlled to produce secreted phosphorylated enzymes. Trials of E R T using such material are in progress for mucopolysaccharidosis I (MPSI), glycogen storage disease type I1 and Fabry disease. Although E R T may disperse the storage material in systemic tissues and organs, it is unlikely to be beneficial in those disorders with involvement of the central nervous system because of the blood-brain barrier. Other sanctuaries from the replacement enzyme may also exist, e.g. bone and joints. Development of antibodies against the exogenous enzyme may be a problem in patients who do not produce any endogenous protein.
In bone-marrow transplantation (BMT), normal donor stem cells differentiate to different lineages that colonize many organs and tissues. Secretion of the normal enzyme by these cells followed by uptake by other cells or perhaps direct transfer of the normal enzyme mediated by cellto-cell contact [18] results in wide distribution of the therapeutic enzyme. Again, BMT has been most successful for disorders that are primarily systemic, e.g. non-neuronopathic Gaucher disease The 8-glucuronidase gene has been introduced directly into the central nervous system of the MPS VII mouse using herpes simplex virus 
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We have been investigating the use of nonviral vectors that exploit receptor-mediated endocytosis to transfect cells from patients with lysosoma1 storage diseases [32] .
Many of these experimental forms of therapy will become available for human use, perhaps in combination to target different rates or sites of storage. Selection of the appropriate therapy will depend on a full knowledge of the molecular basis and cellular pathology in the individual case. 
Introduction
Many protozoa, a few fungi and mature mammalian red blood cells do not harbour mitochondria. This organelle is ubiquitous in all other eukaryotic cells and functions to transform the energy released during substrate oxidation into ATP. Mitochondria contain a compact, extranuclear genome, mitochondrial DNA (mtDNA;
Key words: D-loop, mitochondrial stress, mtDNA, mtDNA transcription. Abbreviations used: mtDNA, mitochondrial DNA; mtRNA, mitochondrial RNA; MRP-RNase, rntRNA processing RNase: mtTFA, mitochondrial transcription factor-A: TH, thyroid hormone: rnTERF. mitochondria1 transcription-termination complex: TAP, thiarnphenicol; HSP. LSP, heavy-and light-strand promoten. Figure 1 ). In humans, this is an approximately 16.5-kb, circular, closed covalent genome that is transcribed from both stands. It encodes 13 essential polypeptides represented in four of the five respiratory chain complexes, and all of the mitochondrion-specific rRNAs and tRNAs necessary for intra-mitochondria1 protein synthesis. The remaining 90 or so proteins constituting the respiratory chain and all proteins involved in mitochondrial function and homoeostasis (greater than lOOO), including those required for mtDNA replication, transcription and translation are encoded by the nucleus, translated in the cytosol and imported into the mitochondrion [l] .
As the respiratory chain is composed of subunits encoded by two distinct genomes and holds the central role in vertebrate energy production, its correct assembly, activity and response to local energy demands and other external stimuli are likely to require complex but tightly coordinated regulatory mechanisms. Supporting this view, cellular mitochondrial content, activity and mtDNA copy number are generally related to the energy demand of the tissue type [2] . Hence, myocytes and neuronal cells contain amongst the largest cellular mtDNA copy number and mitochondrial volume. mtDNA copy number has been shown to increase with increased cellular mitochondrial content and metabolic activity as induced by continual exercise [3] , electrical stimulation of cardiomyocytes [4] , adaptive thermogenesis of myotubes [S] or after thyroid hormone (TH) treatment of liver cells [6] .
